EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer

Sachin Sharma, Kavya Chandra, Aliva Naik, Anamika Sharma, Ram Sharma, Amandeep Thakur, Ajmer Singh Grewal, Ashwani K Dhingra, Arnab Banerjee, Jing Ping Liou, Santosh Kumar Guru, Kunal Nepali

Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2023 · 38 (1)

DOI: 10.1080/14756366.2023.2276665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 02.11.2023. Verfasst von Sachin Sharma und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Endometrial Neoplasms, Flavones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Science and Technology Council, SERB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Structural tailoring of the flavone framework (position 7) via organopalladium-catalyzed C-C bond formation was attempted in this study. The impact of substituents with varied electronic effects (phenyl ring, position 2 of the benzopyran scaffold) on the antitumor properties was also assessed. Resultantly, the efforts yielded a furyl arm bearing benzopyran possessing a 4-fluoro phenyl ring (position 2) (14) that manifested a magnificent antitumor profile against the Ishikawa cell lines mediated through dual inhibition of PARP and tubulin [(IC50 (PARP1) = 74 nM, IC50 (PARP2) = 109 nM) and tubulin (IC50 = 1.4 µM)]. Further investigations confirmed the ability of 14 to induce apoptosis as well as autophagy and cause cell cycle arrest at the G2/M phase. Overall, the outcome of the study culminated in a tractable dual PARP-tubulin inhibitor endowed with an impressive activity profile against endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsEndometrial NeoplasmsFlavonesHumansFemaleTubulin ModulatorsTubulinPoly(ADP-ribose) Polymerase InhibitorsCell Line, TumorDrug Screening Assays, AntitumorApoptosisBenzopyransCell Proliferation

Stichwörter der Autor:innen

FlavonePARPbenzopyranendometrial cancerinhibitortubulin

Substanzen

Tubulin ModulatorsTubulinPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsFlavonesBenzopyrans

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Department of Biological Sciences, BITS Pilani KK Birla Goa campus, Goa, India.
  • Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
  • Guru Gobind Singh College of Pharmacy, Yamuna Nagar, India.
  • Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Science and Technology Council
  • SERB
  • DBT, GOI

Zitieren

APA

Sharma, S., Chandra, K., Naik, A., Sharma, A., Sharma, R., Thakur, A., Grewal, A. S., Dhingra, A. K., Banerjee, A., Liou, J. P., Guru, S. K., & Nepali, K. (2023). Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1). https://doi.org/10.1080/14756366.2023.2276665

Vancouver

Sharma S, Chandra K, Naik A, Sharma A, Sharma R, Thakur A, et al. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023;38(1). doi:10.1080/14756366.2023.2276665

BibTeX
@article{Sharma2023,
  author = {Sharma, Sachin and Chandra, Kavya and Naik, Aliva and Sharma, Anamika and Sharma, Ram and Thakur, Amandeep and Grewal, Ajmer Singh and Dhingra, Ashwani K and Banerjee, Arnab and Liou, Jing Ping and Guru, Santosh Kumar and Nepali, Kunal},
  title = {Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2023},
  volume = {38},
  number = {1},
  doi = {10.1080/14756366.2023.2276665}
}
Kostenlos starten →